Form 4: Precision BioSciences Director Kevin Buehler Acquires 9,826 Restricted Stock Units

Director Kevin Buehler acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences, Inc. on June 4, 2024, which vest on the earlier of June 4, 2025, or the day before the next annual meeting, contingent upon continued service.

Summary

• On June 4, 2024, Kevin Buehler, a director of Precision BioSciences, Inc., acquired 9,826 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Precision BioSciences' common stock or an equivalent cash amount.
• The RSUs will vest on the earlier of June 4, 2025, or the day before the company's next annual meeting of stockholders, provided Buehler remains in service.
• The transaction was reported on June 6, 2024.

Sentiment

Score: 7

Explanation: The acquisition of RSUs by a director is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't provide significant new information.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.
• The vesting schedule incentivizes continued service and commitment from the director.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service to the Issuer through the applicable vesting date.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment.

Key Dates